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ABSTRACT 
Objective: To develop and validate a selective stability indicating high performance liquid chromatographic method for fenoxazoline hydrochloride, 
to carry out its forced degradation and to identify the degradation products using hyphenated techniques like liquid chromatography-mass 
spectrometry, thin layer chromatography-mass spectrometry and tandem mass spectrometry.  
Methods: The optimised chromatographic conditions involved the use of Methanol: 10 mM Ammonium acetate (v/v) with 0.3% triethylamine with 
pH adjusted to 4 using formic acid (55:45) and 0.5 ml/min flow rate. Fenoxazoline hydrochloride was subjected to hydrolytic, oxidative, photolytic 
and thermal stress conditions as per International Conference on Harmonisation guidelines. The degradation products were characterized by liquid 
chromatography-mass spectrometry, tandem mass spectrometry and a novel hyphenated technique, thin layer chromatography-mass spectrometry. 
Fragmentation pathways and degradation pathways of the drug and the degradation products were postulated. 
Results: The drug was found to be highly susceptible to degradation under alkaline conditions. Two degradation products were formed in all the 
stress conditions with aqueous media. This method was validated as per ICH guidelines and was found to comply with the standard norms. The 
calibration curve was found to be linear between 0.07-100 μg/ml. Limit of detection and quantitation was 0.02 μg/ml and 0.07 μg/ml respectively. 
Conclusion: A simple, isocratic and selective stability-indicating high performance liquid chromatographic method has been developed and 
validated for the determination of fenoxazoline hydrochloride. The validated method was found to be linear, precise, accurate and robust. The 
degradation products were identified as 2-(2-isopropylphenoxy)-N-(2-aminoethyl) acetamide and 2-(2-isopropylphenoxy) acetic acid, which are 
novel impurities for fenoxazoline hydrochloride. 
Keywords: Fenoxazoline hydrochloride, Impurities, Forced degradation, Stability indicating method, TLC-MS. 
 
INTRODUCTION 
Impurity profiling is now gaining critical attention from regulatory 
authorities. The presence of impurities, even in a small amount, 
may influence the efficacy and safety of pharmaceutical products. 
A stability indicating method is defined as a validated analytical 
procedure that can accurately and precisely measure active 
ingredients (drug substance or drug product) free from process 
impurities, excipients and degradation products [1]. The 
International Conference on Harmonization (ICH) guideline, Q1A 
(R2) requires forced decomposition of the drugs under conditions 
of hydrolysis, oxidation, photolysis, and thermal stress to 
determine their intrinsic stability and to justify the stability-
indicating nature of the analytical method employed in stability 
studies [2]. It also lays emphasis on the establishment of the 
degradation pathway of the drug. Numerous studies have been 
reported in the literature on the protocol of stress testing [3-5], 
establishment of stability-indicating assays [6-9] and 
characterization of degradation products by carrying out LC–MS 
and MS/MS fragmentation studies [10-13]. 
Fenoxazoline (FEN), chemically known as 2-[(2-propan-2-
ylphenoxy) methyl]-4, 5-dihydro-1H-imidazole (fig. 1) is 
employed as a topical nasal decongestant with rapid and 
prolonged action [14]. FEN is not yet official in any of the 
pharmacopoeias. The purpose of the present study was to 
develop a stability indicating high performance liquid 
chromatographic assay method to separate the drug and its 
degradation products and to characterize the degradation 
products of fenoxazoline using various mass spectrometry 
techniques. Till recently there were no reports of any studies on 
forced degradation of fenoxazoline and development of stability 
indicating method, except for a very recent article which 
describes forced degradation studies of fenoxazoline 
hydrochloride [15]. But our observations and degradation 
products were found to be different.  
 
Fig. 1: Structure of Fenoxazoline hydrochloride (FEN) 
 
MATERIALS AND METHODS 
Chemicals and reagents 
Fenoxazoline hydrochloride was received as a gift sample from 
Precise Chemipharma (Navi Mumbai, Maharashtra, India) and was 
used without further purification. HPLC grade methanol (MeOH), 
Ethyl acetate (EA), Diethylamine (DEA) and analytical reagent (AR) 
grade hydrochloric acid (HCl) was purchased from Merck (Mumbai, 
India). Ammonium acetate (CH3COONH4), hydrogen peroxide (H2O2), 
sodium hydroxide (NaOH) and triethylamine (TEA) were purchased 
from S. D. Fine-Chemicals Ltd. (Mumbai, India) and HPLC grade 
water was prepared by using a quartz double distillation assembly 
of Lab-Sil Instruments (Bangalore, India). 
Instrumentation 
Stability studies 
A stability chamber (Scientico, Mumbai) was used to carry out solid state 
thermal stress studies. Photostability studies were carried out in a 
photostability chamber (Thermolab Scientific Equipments Pvt. Ltd., 
India).  
Liquid chromatography 
The high performance liquid chromatography (HPLC) system was 
Jasco 800 series fitted with a 20 µl injection loop and a series 975 UV 
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detector. The output signal was monitored and processed using 
Borwin software. The components were separated using Inertsil 
ODS 3V (150 x 4.6 mm, 5 µm) column and 10 mM ammonium 
acetate: methanol (45:55) as the mobile phase in an isocratic mode. 
The wavelength used was 220 nm. Flow rate was adjusted to 0.5 
ml/min as lower LC flow rates are generally preferred for LC-MS 
since the MS operates under vacuum and can only handle a limited 
load generated from the LC eluent [16]. 
LC-MS  
LC-MS studies of drug and degradants were carried out on Waters 
Micromass-Quatramicro API system. Conditions for degradation 
products: Degradation product 1 (DP1): Capillary voltage, 3.14 KV; 
Cone voltage, 10 V; Extractor, 2; Rf lens; 0.2; Temperature: Source 
temperature, 100 °C; Desolvation temperature, 300 °C. Varying 
conditions for degradation product 2 (DP2): Capillary voltage, 3.10 
KV; Extractor, 5.  
MS/MS  
MS/MS studies were carried out using an Applied Biosystems MDS 
SCIEX system. Triple quadrupole mass spectrometric analysis was 
performed on API Applied Biosystems Hybrid Q-Trap API 2000 Mass 
Spectrometer (AB-MDS Sciex, Toronto, Canada) equipped with 
electrospray ionization source (ESI). Data acquisition and analysis were 
performed using Analyst software 1.3.1 (AB SCIEX, USA). The mass 
spectrometer was run in positive and negative electrospray ionization 
(ESI) mode with mass to charge (m/z) ratio in the range of 50–300 m/z.  
The operating conditions for MS scan for FEN and DP1 were: A) 
Compound dependent parameters: Declustering potential (DP), 
60.00 V; Entrance potential (EP), 10.00 V; Collision Entrance 
Potential (CEP), 10.00 V; Collision Energy (CE), 35.00 eV; Collision 
Exit Potential (CXP) 4.00 V B) Gas Parameters: Curtain gas (CUR), 
15.00 psi; GS1 (nebulizer gas), 80.00 psi; GS2 (Heater gas), 20.00 psi; 
Ionisation potential (ISP) 4000.00 V; CAD, Medium. 
The operating conditions for MS scan for DP2 were: A) Compound 
dependent parameters: Declustering potential (DP),-50.00 V; Entrance 
potential (EP),-10.00 V; Collision Entrance Potential (CEP),-12.49 V; 
Collision Energy (CE),-25.00 eV; Collision Exit Potential (CXP), -5.00 V; 
B) Gas Parameters: Curtain gas (CUR), 15.00 psi; GS1 (nebulizer 
gas), 80.00 psi; GS2 (Heater gas), 20.00 psi; Ionisation potential 
(ISP),-3920.00 V; CAD, Medium. 
HPTLC and TLC-MS  
High performance thin layer chromatography was carried out using 
Camag Linomat 5 and the densitometer used was Camag Scanner IV. For 
carrying out TLC-MS analysis Camag TLC-MS interface and LCMS-2020 
(Shimadzu Corporation, Japan) was used. The operating conditions for 
MS scan: Desolvation line temperature: 250 °C; Nebulising gas: 1.5 l/min; 
Heating block: 450 °C; drying gas: 15 l/min 
Forced degradation studies 
FEN was subjected to different stress conditions such as 
hydrolysis, oxidation, dry heat and photolysis. A stock solution 
of 1000 µg/ml of the drug was prepared in methanol. This was 
used further for all the stress studies. FEN was subjected to 
hydrolytic decomposition under acidic condition using 5 N HCl 
for 48 h at 60 °C, under basic condition using 0.1 N NaOH for 25 
min at room temperature, and under neutral condition with 
water at 60 °C for 3 h. For oxidative stress, the drug was treated 
with 30% H2O2 at room temperature for a month. For thermal 
degradation, the solid drug and its 1% solution form in water 
were heated in a stability chamber at a temperature of 40 
°C/75% relative humidity (RH) for 24 h. For photolytic 
degradation, the solid drug and its 1% solution form in water 
was exposed to 1.2 million lux h fluorescent light and 200 
Wh/m2 of UV light. After the specified time intervals the samples 
were collected and stored in the refrigerator at 4 °C.  
Sample preparation 
In case of all the stress conditions, samples were diluted with mobile 
phase to achieve a concentration of 50 µg/ml. The samples from acid 
and base hydrolytic conditions were initially neutralized with 
equivalent strength of base or acid respectively and further diluted 
with mobile phase. 
Validation 
Specificity 
To perform specificity a mixture was prepared by combining the 
stressed solutions. The solution was evaluated for resolution of the 
drug from the generated impurities.  
Linearity 
For linearity, solutions were prepared from stock solution at 
concentration levels from 0.07-100 μg/ml of analyte concentration. 
The graph of peak area versus concentration was plotted by least-
squares linear regression analysis.  
LOD and LOQ 
LOD and LOQ were calculated directly from the calibration plot. The 
limits of detection (LOD) and quantification (LOQ) were calculated 
as 3.3σ/S and 10σ/S, respectively, where σ is the standard deviation 
of intercept and S is the slope of the calibration plot.  
Precision 
Precision was determined by measuring the intra-day precision and 
the inter-day precision, both expressed as RSD (%). It was evaluated 
at three concentrations levels of 20, 40 and 60 μg/ml in bulk drug 
sample, in triplicates.  
Accuracy  
Accuracy was determined by carrying out recovery studies. It was 
evaluated at three concentrations levels of 20, 40 and 60 μg/ml in 
bulk drug sample, in triplicates.  
Robustness 
Robustness was performed by carrying out deliberate changes in 
flow rate (±0.1 ml/min), mobile phase ratio (±1 ml) and pH of the 
mobile phase (±0.2 units).  
Isolation of the impurities 
In order to characterize the impurities, it was decided to carry out 
isolation to obtain a pure form of the impurities. The isolation was 
carried out using preparative high performance thin layer 
chromatography (HPTLC). The method developed, employed HPTLC 
aluminium plates precoated with silica gel 60F-254 as the stationary 
phase. Method development was carried out with various mobile 
phase systems to achieve a good separation. A mixture of acid and 
base stress condition samples was used as the sample for isolation. 
Densitometric scanning was performed using Densitometer scanner 
IV. The plate was kept in the TLC visualizer and the drug and 
impurity bands were marked. The selected areas were then cut out 
along with the silica, in thin long strips. The impurities and drug 
were then extracted from the silica gel with methanol and the 
extracts were pooled. The pooled extract was filtered and the 
solvent was evaporated to constant weight. 
RESULTS AND DISCUSSION 
Stress studies and development of stability indicating assay 
method 
Stability indicating assay methods can be of two types, specific 
stability indicating assay method and selective stability indicating 
assay method. ‘Specific stability-indicating assay method (Specific 
SIAM)’ can be defined as ‘a method that is able to measure 
unequivocally the drug(s) in the presence of all degradation 
products.’ ‘Selective stability-indicating assay method (Selective 
SIAM)’ can be defined as ‘a method that is able to measure 
unequivocally the drug(s) and all degradation products [9].’ The 
second method can be used for assay of the drug as well as for 
quantifying the impurities. The authors have developed a selective 
stability indicating assay method for FEN. Since impurity standards 
were not available, validation for only the drug peak was performed. 
Fenoxazoline degraded to give two products, after it was exposed to 
different stress conditions. The degradants were labeled as 
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degradation product 1 (DP1) and degradation product 2 (DP2) in 
the sequence of their elution. The retention time of the drug was 
found to be 7.9 min and retention times of the DP1 and DP2 were 
observed to be 9.5 and 24.5 min respectively. All stress conditions 
lead to the formation of a common degradation product, DP1. 
Degradation product 2 (DP2) was observed in both acid hydrolysis 
and oxidative stress conditions. Under acid hydrolysis, the drug 
degraded (12.92%) to form two products DP1 and DP2 after exposure 
to 5 N HCl for 48 h at 60 °C. In case of neutral hydrolysis, the drug 
degraded (16.75%) to form DP1, when the drug was exposed to water 
at 60 °C for 3 h. Under base hydrolysis, the drug was found to degrade 
(14.69%) to form DP1 within 25 minutes of exposure to 0.1 N NaOH at 
room temperature. The drug was found to be highly susceptible to 
degradation in basic condition as bases are known to be stronger 
nucleophiles. The degradation was slower in case of neutral hydrolysis 
and much slower in case of acid hydrolysis. The drug degraded to form 
DP1 when it was treated with 30% H2O2 for four days at room 
temperature. Unlike acid hydrolysis, degradation of DP1 to form DP2 
was observed only when the drug was treated further for a month. The 
drug was exposed to heat in a stability chamber at 40 °C±2 °C/75% 
RH±5% RH for 24 h in both solid as well as in solution forms. The drug 
in solid form was found to be stable. However, in solution form, the 
drug was found to degrade to form DP1. The drug was exposed to 1.2 
million lux h of fluorescent light and 200 Wh/m2 UV light in both the 
solid form as well as in the solution form. The drug in solid form was 
found to be stable. However, in solution form, the drug degraded to 
form DP1. The degradation exceeded 20% in oxidation, thermal and 
photolytic stress conditions. The percent degradation for all the stress 
conditions was calculated by area normalization method considering 
the response factor of all the components to be 1. 
A solution was prepared by mixing the stress samples in which the 
degradants were observed. This solution was analyzed using the 
developed HPLC method. Chromatogram of mixed stressed sample 
showing the separation of the drug FEN and the two degradation 
products is shown in fig. 2. 
 
 
Fig. 2: HPLC Chromatogram of mixed stressed sample showing the separation of the drug FEN and the two degradation products namely 
DP1 and DP2 
 
The developed LC method was able to separate the impurities 
from the drug as well as from each other, hence the method can 
be said to be a selective stability indicating method. This method 
can be used for quantification of the drug since all the impurities 




The method was found to be specific and stability indicating as the 
degradants were well resolved from the drug and from one another. 
The resolution was observed to be>2 for all the peaks (fig. 2).  
Linearity 
The response of the drug was found to be linear over the 
concentration range from 0.07 µg/ml-100 µg/ml (r2=0.999). The 
equation of the line was observed to be y= 74914x+11452.  
LOD and LOQ 
Limit of detection, LOD was calculated to be 0.02 µg/ml and the limit 
of quantitation, LOQ was calculated to be 0.07 µg/ml using standard 
deviation of the response and the slope method [17]. 
Precision 
The percent RSD was found to be less than 2% for both intra-day 
and inter-day precision which indicates that the method is precise. 
Precision data is represented in table 1.  
Accuracy 
Mean recovery of the drug was observed to be 101.36% which suggests 
that the method is accurate. Recovery data is presented in table 2. 
Robustness 
It was observed that deliberate changes made in the method with 
regards to the flow rate, mobile phase ratio and the pH of the mobile 
phase did not cause any significant changes in the resolution, 
accuracy and precision indicating that the method is robust. 
Isolation of impurities 
No thin layer chromatographic method for FEN and its degradation 
products has been reported. There are reports on thin layer 
chromatographic analysis of antazoline, an analogue of fenoxazoline 
for separation of the drug from its degradation products [18]. 
Different mobile phase compositions were tried to achieve a good 
separation of the drug from its degradation products. The mobile 
phase Ethyl acetate: Methanol: Diethylamine (7.5:2:0.5) was found 
to give a good resolution between the drug and its degradation 
products (fig. 3). However, the yield obtained after isolation was 
very low. A newer hyphenated technique, TLC-MS was explored in 
this study for identification of the degradation products. 
TLC-MS studies 
TLC-MS Interface 
TLC is a fast and a relatively inexpensive chromatographic method 
for separating complex mixtures and mass spectrometry (MS) is a 
suitable technique for identification due to its high sensitivity [19]. 
Coupling of thin layer chromatography (TLC) and mass 
spectrometry (MS) opens up new possibilities for both techniques. 
TLC-MS interface can semi-automatically extract zones of interest 
and direct them online into HPLC-MS systems. This technique has 
been quite widely explored in the field of forensic sciences [19-21] 
and for determination of analytes in different biological matrices 
[22]. The authors have tried to explore this technique for 
identification of degradation products of fenoxazoline.  
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For carrying out TLC-MS, a TLC plate was developed using the 
optimised conditions mentioned earlier. The developed plate was 
kept in the UV chamber and the bands were marked. This plate was 
placed on the interface which was positioned between the HPLC 
system and the mass spectrometer. The precise positioning of the 
elution head is done semi-automatically with the help of a laser 
pointing device. After extraction, the eluent is directed to the mass 
spectrometer.
 
Table 1: Intra-day and inter-day precision 
Actual concentration (µg/ml) Intraday precision 
(µg/ml)±SD; %RSD (n=3) 
Interday precision 
(µg/ml)±SD; %RSD (n=3) 
20 21.07±0.16; 0.79 21.03±0.16; 0.76 
40 40.3±0.15; 0.38 40.34±0.30; 0.74 
60 60.48±0.34; 0.56 60.6±0.41; 0.68 
 
Table 2: Recovery 
Amount added Amount recovered % Recovery±SD (n=3) 
20 20.35 101.27±0.79 
40 40.52 101.22±0.39 
60 61.02 101.60±0.63 
 
 
Fig. 3: Separation of impurities by HPTLC 
 
 
Fig. 4: TLC-MS spectrum of (A) Fenoxazoline (B) DP1 (C) DP2 
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Fig. 5: TLC-MS of Blank in positive ionisation mode 
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Fig. 6: TLC-MS of Blank in negative ionisation mode 
 
The spectra obtained, are shown in the fig. 4A, 4B and 4C. The MS 
conditions were first optimized for the drug and then the same 
conditions were tried for DP1 and DP2. A blank spectrum was taken 
in both positive and negative ESI modes (fig. 5 and fig. 6). The peaks 
which were observed in the blank spectra were not taken into 
consideration during interpretation of the spectra. The molecular 
ions m/z 219 for the drug, m/z 237 for DP1 could be observed as 
shown in fig. 4A and 4B respectively. However, when the same 
conditions were applied to DP2, no molecular ion peak was 
observed. Negative ionization mode was tried for DP2. A number of 
low intensity molecular ion peaks were observed (fig. 4C), making it 
very difficult to unmistakably identify the molecular ion for DP2. The 
drug and DP1 were observed in positive ESI mode. The high 
intensity peaks which were observed in both the blank as well as the 
sample could have led to a lower relative intensity of the molecular 
ion peaks of the degradation products. 
LC-MS studies of the drug and degradation products 
For confirmation of the identity of the impurities, LC-MS studies 
were also carried out. For this, the developed HPLC method with 
slight modification was employed. Triethylamine tends to cause 
persistent background problems with the MS system and hence was 
not used during the analysis [23, 24]. This caused a shift in the 
retention times of the drug and the degradation products. The rest of 
the conditions were kept the same as those used for the HPLC 
method. 
A mixture of stressed samples (acid, base, neutral and oxidation) 
was injected into the system. The parameters for analysis were 
optimized to obtain information about the molecular ion peak of the 
drug. The LC-MS spectrum is shown in fig. 7. The molecular weight 
of FEN is 218.29. [M+H]+ion of m/z 219 (fig. 7A) was observed in the 
positive ESI mode. The impurity peak of DP1 showed an [M+H]+ion 
at m/z 237(fig. 7B) in the positive ESI mode indicating that the 
molecular weight of DP1 is 236. However, when the same 
parameters were applied to DP2, it did not show any molecular ion 
peak. The impurity peak of DP2 showed an [M-H]-ion at m/z 193 (fig. 
7C) in the negative ionization mode indicating that the molecular 
weight of DP2 is 194 and DP2 could possibly be having an acidic 
functional group. Tandem MS/MS studies were carried out on the 
drug and the degradation products to confirm these predictions. 
Characterization of the degradation products using MS/MS  
Tandem MS was performed by infusing the stress samples into the mass 
spectrometer via the syringe pump. Both positive mode and negative 
mode of electrospray ionization were used for analysis. The parameters 
for analysis were initially optimized to carry out the fragmentation of the 
molecular ion peak of the drug, followed by DP1 and DP2. 
  
 
Fig. 7: LC-MS spectra of mixed stress sample (A) [M+H]+ion of FEN (B) [M+H]+ion of DP1 (C) [M-H]-ion of DP2 
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 Fragmentation pathway 
The mass spectrum of the drug can be observed in fig. 8A. The 
MS/MS analysis of the drug (m/z 219) gave a product ion at m/z 
83.8 (fig. 8B). The MS/MS analysis of the DP1 (m/z 237) gave four 
product ions at m/z 220.3, 178.1, 148.9 and 84.9 (fig. 8C). Fragment 
ion of m/z 220 has a difference of 17 amu from that of DP1, which 
could be attributed to the loss of an ammonium ion. The fragment 
ion m/z 84.9 is formed on further fragmentation occurring in the 
fragment ion of m/z 220. A difference of 58.9 amu between DP1 and 
the fragment ion at m/z 177.09 can be attributed to the loss of 
ethane-1, 2-diamine. DP1 undergoes α-fission leading to the 
fragment ion m/z 148.9 owing to a loss of N-(2-aminoethyl) 
formamide of mass 88.07. 
The MS/MS analysis of DP2 (m/z 193) gave two product ions at m/z 
135 and 149. Fragment ion of m/z 135 has a difference of 58 amu 
which can be attributed to loss of acetic acid from the moiety. 
Fragment ion m/z 149 is formed by a neutral loss of carbon dioxide 
of 44 amu (fig. 8D). Indumati et al. have carried out forced 
degradation of FEN and identified the degradation products [15]. 
The reported masses of the degradation products are very different 
from the masses reported in this study. No other impurities were 
observed under the stress conditions employed in the present study. 
It was observed that FEN was highly susceptible to alkaline 
conditions and a degradation of 14.69% was observed within 25 min 
of exposure to 0.1 N NaOH at room temperature. Extensive exposure 
to alkaline conditions caused the drug to degrade entirely. The 
authors have carried out tandem mass spectrometry and elucidated 
the structures from the fragments that were observed. The 
fragmentation pathway is depicted in fig. 9. From the elucidated 
structures of the degradation products, the most probable 
degradation pathway of the drug was postulated. 
  
 
Fig. 8: (A) Mass spectrum of the fenoxazoline (B) MS/MS spectrum of fenoxazoline(C) MS/MS Spectrum of DP1 (D) MS/MS spectrum of DP2 
 
 
Fig. 9: Mass fragmentation pathways for fenoxazoline, DP1 and DP2 
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Degradation pathway  
DP1 showed a molecular ion peak at m/z 237 which has a difference 
of 18 amu from the molecular ion peak of the drug m/z 219. This can 
be attributed to addition of water moiety to the drug molecule. 
During hydrolysis, the nucleophilic attack of water takes place and 
leads to ring opening. This further undergoes amide–iminol 
tautomerism leading to formation of DP1. There are reports of 
degradation studies on antazoline and naphazoline, both containing 
imidazoline rings, wherein the imidazoline ring present in the 
structure opens up to form the amide form of the molecule on 
hydrolysis, and shows a difference of 18 amu between the molecular 
weights of the degradation products and the drug itself [25, 26].  
It can be suggested that FEN underwent the same kind of 
degradation. DP2 had a molecular weight of 194 amu which has a 
difference of 24 amu from the molecular weight of FEN. It can be 
suggested that DP1 further undergoes amide hydrolysis to form an 
acid DP2. Korodi T. et al. have reported a degradation impurity of 
naphazoline, 1-naphthylacetic acid [26]. This impurity shows a 
difference of 24 amu from the molecular weight of naphazoline. It 
can be suggested that FEN could have also undergone the same 
process leading to formation of DP2. The degradation pathway is 
depicted in fig. 10. 
 
 
Fig. 10: Degradation pathway of Fenoxazoline to form DP1 and DP2 
 
CONCLUSION 
A simple and an isocratic HPLC-UV selective stability indicating 
assay method was developed and validated for Fenoxazoline 
hydrochloride for the first time. It underwent degradation in all the 
stress conditions to form two impurities DP1 and DP2. It was found 
to be highly labile to alkaline conditions leading to formation of DP1. 
DP1 was formed in presence of water by hydrolysis of the drug, with 
the imidazoline ring opening to give the amide form. This amide 
hydrolysed further to give the carboxylic acid DP2. A newer 
technique TLC-MS was explored for structural elucidation of the 
degradation products and the results were confirmed by LC-MS and 
MS/MS studies. The molecular masses of the degradation products 
were obtained by recording MS/MS scans in both+ESI and–ESI 
modes. DP1 was found to be 2-(2-isopropylphenoxy)-N-(2-
aminoethyl) acetamide and DP2 was found to be 2-(2-
isopropylphenoxy) acetic acid. Degradation and fragmentation 
pathways for both degradation products were postulated.  
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